<DOC>
	<DOCNO>NCT00045786</DOCNO>
	<brief_summary>The primary objective study assess safety CC-1088 patient myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>Study Determine Safety Preliminary Efficacy CC-1088 Treatment Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Eligible patient must diagnosis MDS least 12 week therapy relate . Patient must able adhere study visit schedule protocol requirement . Patient must understand voluntarily sign informed consent document . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test . Women must pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2004</verification_date>
	<keyword>myelodysplastic syndrome</keyword>
</DOC>